Aspirin‑Free Antiplatelet Management for Patients with Confirmed Aspirin Allergy Undergoing PCI

1. Stent Selection

• Drug‑eluting stents (DES) are preferred for most aspirin‑allergic patients because they markedly lower restenosis compared with bare‑metal stents, and contemporary DES have been validated in large randomized trials that focus on antiplatelet strategy rather than stent type. (European Society of Cardiology) 1
• Bare‑metal stents (BMS) may be chosen when only a 1‑month duration of antiplatelet therapy is feasible (e.g., imminent non‑cardiac surgery) because BMS require only 1 month of dual antiplatelet therapy. (American Heart Association) 2

2. Initial Aspirin‑Free Antiplatelet Regimen (First 1–3 Months Post‑PCI)

2.1 Dual P2Y12 Inhibitor Therapy (Preferred if Tolerated)

• Loading dose of clopidogrel 600 mg plus ticagrelor 180 mg at the time of stent implantation, followed by clopidogrel 75 mg daily + ticagrelor 90 mg twice daily for 1–3 months. This regimen demonstrated reduced major bleeding without an increase in thrombotic events in patients requiring anticoagulation. (European Society of Cardiology) [1][3]
• Evidence from a randomized trial in anticoagulated patients showed a lower bleeding rate (hazard ratio ≈ 0.70) and no difference in stent thrombosis or myocardial infarction with dual P2Y12 therapy versus traditional aspirin‑containing DAPT. (American College of Cardiology) [4][5]

2.2 Single P2Y12 Inhibitor Therapy (If Dual Therapy Not Tolerated)

• Loading with either clopidogrel 600 mg or ticagrelor 180 mg, then continuation with the chosen agent alone (clopidogrel 75 mg daily or ticagrelor 90 mg twice daily) for 1–3 months. This approach is acceptable when dual P2Y12 therapy cannot be given, acknowledging a modestly higher theoretical risk of stent thrombosis. (European Society of Cardiology) [1][3]

3. Long‑Term Maintenance (After Initial 1–3 Months)

• Transition to P2Y12 inhibitor monotherapy for the remainder of the first year after PCI. (European Society of Cardiology) [1][3]
• Ticagrelor 90 mg twice daily is preferred over clopidogrel for long‑term monotherapy because recent trials showed a lower composite of ischemic events and major bleeding. (European Society of Cardiology) 3
• Clopidogrel 75 mg daily remains an acceptable alternative when ticagrelor is contraindicated or not tolerated. (European Society of Cardiology) [1][3]
• P2Y12 inhibitor monotherapy should be continued for at least 12 months from the index PCI; thereafter, continuation is individualized based on ischemic versus bleeding risk. (European Society of Cardiology) [1][3]

4. Clinical Scenario‑Specific Recommendations

4.1 Acute Coronary Syndrome (ACS)

• Use DES with the dual P2Y12 inhibitor regimen (clopidogrel + ticagrelor) for the first 1–3 months, reflecting the higher thrombotic risk in ACS. (European Society of Cardiology) [1][5]
• Switch to ticagrelor monotherapy after the initial period and maintain for at least 12 months. (European Society of Cardiology) 3
• Avoid BMS in ACS unless absolutely unavoidable, because the ischemic risk outweighs the benefit of a shorter antiplatelet duration. (European Society of Cardiology) 1

4.2 Stable Coronary Artery Disease

• Both DES and BMS are reasonable; if DES are used, the abbreviated 1–3 month dual P2Y12 regimen followed by monotherapy is supported by evidence showing no increase in ischemic events and a reduction in bleeding. (European Society of Cardiology) [1][3]
• If BMS are selected, a 1‑month course of a single P2Y12 inhibitor followed by indefinite monotherapy is acceptable. (European Society of Cardiology) [1][3]

4.3 High Bleeding‑Risk Patients

• Prefer BMS with 1 month of clopidogrel monotherapy (no dual therapy) and continue clopidogrel indefinitely. (European Society of Cardiology) 1
• When DES are required, limit dual P2Y12 therapy to 1 month before transitioning to single‑agent therapy. (European Society of Cardiology) [1][3]
• Clopidogrel is favored over ticagrelor in this subgroup because it is associated with lower major bleeding rates. (European Society of Cardiology; American Heart Association) [1][5]

5. Safety and Monitoring

• Premature discontinuation of the P2Y12 inhibitor is the strongest predictor of stent thrombosis; adherence to the minimum recommended duration (≥1 month for BMS, ≥1–3 months for DES) is essential. (European Society of Cardiology) 1
• Confirm true IgE‑mediated aspirin allergy (anaphylaxis, angioedema, severe urticaria) before adopting aspirin‑free regimens; differentiate from non‑allergic intolerance. (American Heart Association) 2
• Proton‑pump inhibitor prophylaxis should be given to all patients on P2Y12 inhibitors, especially during the dual‑therapy phase, to mitigate gastrointestinal bleeding. (American Heart Association) [5][6]
• Platelet function testing is not recommended to guide de‑escalation of therapy, as it lacks validation and has been linked to adverse outcomes. (European Society of Cardiology) 7

6. Common Pitfalls to Avoid

• Do not prescribe aspirin monotherapy in patients with confirmed aspirin allergy. (European Society of Cardiology) [1][3]
• Do not discontinue all antiplatelet agents within the first year after PCI; at minimum, maintain a single P2Y12 inhibitor. (European Society of Cardiology) 1
• Avoid prasugrel in aspirin‑free regimens because it has not been studied in dual P2Y12 combinations and carries a higher bleeding risk. (European Society of Cardiology; American Heart Association) [1][2]5
• Do not extend dual P2Y12 therapy beyond 3 months unless the patient has a documented very high thrombotic risk, as prolonged dual therapy markedly increases bleeding. (European Society of Cardiology) 1

Antiplatelet Therapy Requirements for Coronary Stents

Introduction to Coronary Stent Antiplatelet Therapy

• The American Heart Association recommends that all coronary stents require at least some duration of antiplatelet medication to prevent stent thrombosis, which carries a 40-64% risk of death or myocardial infarction 8, 9

Bare-Metal Stents (BMS) Protocol

• The American College of Cardiology recommends bare-metal stents require the shortest duration of dual antiplatelet therapy (DAPT)—only 1 month—making them the closest option to "not requiring" prolonged antiplatelet therapy 9, 10, 11
• The European Society of Cardiology suggests DAPT (aspirin + clopidogrel) for 1 month minimum, followed by aspirin monotherapy indefinitely thereafter 9, 10, 11
• Loading doses: aspirin 325 mg + clopidogrel 600 mg at time of stenting, with a maintenance dose of aspirin 75-100 mg daily + clopidogrel 75 mg daily 8, 9, 11

Drug-Eluting Stents (DES) Protocol

• The American Heart Association recommends all drug-eluting stents require significantly longer DAPT duration—6-12 months minimum—followed by aspirin monotherapy indefinitely thereafter 8, 9, 10, 11
• Specific durations historically varied by stent type: sirolimus DES (3 months), paclitaxel DES (6 months), but current guidelines recommend 12 months for all DES 8, 10

Special Populations Requiring Modified Antiplatelet Regimens

• The American College of Cardiology suggests that patients on chronic oral anticoagulation should use bare-metal stents or BioFreedom DES when possible, with triple therapy (warfarin + aspirin + clopidogrel) for 1 month only (for BMS), then warfarin + clopidogrel alone 9, 12
• The European Society of Cardiology recommends that patients requiring urgent surgery within 30 days of stenting should proceed to surgery without stopping antiplatelet therapy if bleeding risk permits, and if surgery can be deferred 30 days, use BMS and stop DAPT after 30 days 10

Risks of Premature DAPT Discontinuation

• The American Heart Association warns that stopping antiplatelet therapy prematurely is the single strongest predictor of stent thrombosis, with a hazard ratio of 161 for subacute thrombosis and 57 for late thrombosis 13, 14
• The risk of stent thrombosis is 29% in patients who prematurely discontinued DAPT, with a mortality rate from stent thrombosis of 20-45% and a death or MI rate with documented stent thrombosis of 64.4% 8, 13, 14